09:52 AM EST - QLT Inc. : announced today that Valeant Pharmaceuticals International, Inc. has acquired Visudyne®, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc. Valeant paid $62.5 million upfront for all U.S. rights and available inventories for Visudyne, which had U.S. revenue of approximately $21 million in 2011, and another $50 million upfront for rights to non-U.S. royalties on Visudyne sales, which were approximately $14 million in 2011. QLT Inc.
shares T.QLT are trading up $0.55 at $7.96.
